Antibody therapeutics are a cornerstone of modern medicine, driving transformative treatments for cancer, autoimmune, and infectious diseases. Monoclonal antibodies (mAbs) remain the most widely used format, supported by decades of research and proven manufacturing platforms. Yet despite their success, mAbs present ongoing purification challenges — including host cell impurities, aggregation, and variability across expression systems.
As antibody engineering advances, new formats such as antibody fragments (Fab, scFv) and bispecific antibodies (bsAbs) are expanding therapeutic possibilities. These novel formats offer advantages such as improved tissue penetration, faster clearance, or simultaneous targeting of multiple disease mechanisms. However, their unique structures also increase complexity in downstream processing, where conventional affinity methods like Protein A may not always be sufficient.
To meet these challenges, a flexible, toolbox-based purification strategy is essential. At Astrea Bioseparations, our portfolio of chromatography solutions is designed to address the evolving landscape of mAb and bsAb purification, delivering scalable, high-performance tools that ensure purity, yield, and consistency for next-generation antibody therapeutics.